Reduced acute toxicity associated with the use of volumetric modulated arc therapy for the treatment of adenocarcinoma of the prostate

Practical Radiation Oncology

Volumn 3, Issue 4, 2013, Pages

  Hall, William A ^a   Colbert, Lauren ^a   Nickleach, Dana ^b   Shelton, Joseph ^a   Marcus, David M ^a   Switchenko, Jeffrey ^b   Rossi, Peter J ^a   Godette, Karen ^a   Cooper, Sherrie ^a   Jani, Ashesh B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACUTE COMMON TOXICITY CRITERIA FOR ADVERSE EVENT SCORE; ACUTE TOXICITY; ADULT; AGED; ARTICLE; BLADDER DISEASE; CANCER RADIOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RECTUM DISEASE; SCORING SYSTEM; VOLUMETRIC MODULATED ARC THERAPY;

EID: 84884354185     PISSN: 18798500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prro.2013.01.003     Document Type: Article

References (20)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Jani A.B., Hellman S. Early prostate cancer: clinical decision-making. Lancet 2003, 361:1045-1053.
3. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002, 53:1111-1116.
4. Zelefsky M.J., Fuks Z., Happersett L., et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000, 55:241-249.
5. Wolff D., Stieler F., Welzel G., et al. Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiother Oncol 2009, 93:226-233.
6. Yu C.X. Intensity-modulated arc therapy with dynamic multileaf collimation: an alternative to tomotherapy. Phys Med Biol 1995, 40:1435-1449.
7. Otto K. Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys 2008, 35:310-317.
8. Kupelian P.A., Langen K.M., Zeidan O.A., et al. Daily variations in delivered doses in patients treated with radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2006, 66:876-882.
9. Aznar M.C., Petersen P.M., Logadottir A., et al. Rotational radiotherapy for prostate cancer in clinical practice. Radiother Oncol 2010, 97:480-484.
10. Davidson M.T., Blake S.J., Batchelar D.L., Cheung P., Mah K. Assessing the role of volumetric modulated arc therapy (VMAT) relative to IMRT and helical tomotherapy in the management of localized, locally advanced, and post-operative prostate cancer. Int J Radiat Oncol Biol Phys 2011, 80:1550-1558.
11. Ost P., Speleers B., De Meerleer G., et al. Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study. Int J Radiat Oncol Biol Phys 2011, 79:920-926.
12. Palma D., Vollans E., James K., et al. Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72:996-1001.
13. Shelton J., Rossi P.J., Chen H., Liu Y., Master V.J., Jani A.B. Observations on prostate intrafraction motion and the effect of reduced treatment time using volumetric modulated arc therapy. Pract Radiat Oncol 2011, 1:243-250.
14. Li H.S., Chetty I.J., Enke C.A., et al. Dosimetric consequences of intrafraction prostate motion. Int J Radiat Oncol Biol Phys 2008, 71:801-812.
15. Michalski J.M., Winter K., Purdy J.A., et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys 2005, 62:706-713.
16. Program CTE Common terminology criteria for adverse events, version 3.0 2006, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Washington, DC.
17. De Meerleer G., Vakaet L., Meersschout S., et al. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 2004, 60:777-787.
18. Teh B.S., Mai W.Y., Uhl B.M., et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose-volume analysis. Int J Radiat Oncol Biol Phys 2001, 49:705-712.
19. Vlachaki M.T., Teslow T.N., Amosson C., Uy N.W., Ahmad S. IMRT versus conventional 3DCRT on prostate and normal tissue dosimetry using an endorectal balloon for prostate immobilization. Med Dosim 2005, 30:69-75.
20. Ali A.N., Rossi P.J., Godette K.G., et al. Impact of magnetic resonance imaging on computed tomography-based treatment planning and acute toxicity for prostate cancer patients treated with IMRT. Pract Radiat Oncol 2013, 3:E1-E9.